{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T20:45:19Z","timestamp":1790801119931,"version":"4.1.0"},"reference-count":57,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pediatr."],"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>Riociguat, an oral soluble guanylate cyclase stimulator, has been approved for use in adults with pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension. However, there is limited data on its therapeutic use in children.<\/jats:p><\/jats:sec><jats:sec><jats:title>Case Presentation<\/jats:title><jats:p>We report the case of two infants with severe suprasystemic pulmonary hypertension who were successfully treated with riociguat after failure to wean off inhaled nitric oxide (iNO) despite combination PAH therapy. Case 1 is a 6-month-old term male with TBX4 deletion who presented with severe hypoxemic respiratory failure and severe PAH immediately after birth. Initial cardiac catheterization showed PVRi 15.5 WU*m2. Marked hypoxemia and PAH persisted despite aggressive therapy with sildenafil, bosentan, intravenous treprostinil, and milrinone. The infant required high doses of inhaled nitric oxide (60\u2005ppm) and manifested significant post-ductal hypoxemia and hemodynamic instability with any attempt at weaning. After discontinuation of sildenafil, initiation, and very slow uptitration of riociguat, the patient was able to maintain hemodynamic stability and wean from nitric oxide over 6 weeks with persistently severe but not worsened pulmonary hypertension. Case 2 is a 4-month-old term male with compound heterozygous SLC25A26 mutation and severe pulmonary hypertension. Initial cardiac catheterization showed PVRi 28.2 WU*m2. After uptitration of sildenafil, bosentan, and IV treprostinil, serial echocardiograms continued to demonstrate near-systemic pulmonary hypertension. He failed multiple attempts to wean off typical doses of iNO (10\u201320\u2005ppm) over the following weeks with tachypnea, hypoxemia, and worsening pulmonary hypertension on echocardiogram despite continued aggressive combination targeted therapy. After a 24-h sildenafil washout, he was initiated and uptitrated on riociguat with concomitant, successful wean of nitric oxide over one week that was well tolerated. No serious adverse effects in the titration period were observed.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Riociguat may be considered as an adjuvant therapeutic agent in selected children with severe PAH who are poorly responsive to sildenafil therapy and unable to wean from iNO.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fped.2022.1014922","type":"journal-article","created":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T12:30:18Z","timestamp":1669897818000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":22,"title":["Novel use of riociguat in infants with severe pulmonary arterial hypertension unable to wean from inhaled nitric oxide"],"prefix":"10.3389","volume":"10","author":[{"given":"L. T.","family":"Domingo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D. D.","family":"Ivy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S. H.","family":"Abman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. M.","family":"Grenolds","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. T.","family":"MacLean","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. A.","family":"Breaux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K. J.","family":"Minford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B. S.","family":"Frank","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,12,1]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1016\/j.pcl.2020.06.005","article-title":"Pediatric pulmonary arterial hypertension","volume":"67","author":"Frank","year":"2020","journal-title":"Pediatr Clin N Am"},{"key":"B2","doi-asserted-by":"publisher","first-page":"1477","DOI":"10.1161\/01.CIR.0000029100.82385.58","article-title":"Survival in primary pulmonary hypertension: the impact of epoprostenol therapy","volume":"106","author":"McLaughlin","year":"2002","journal-title":"Circulation"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.121.024969","article-title":"Mortality in pulmonary arterial hypertension in the modern era: early insights from the pulmonary hypertension association registry","volume":"11","author":"Chang","year":"2022","journal-title":"J Am Heart Assoc"},{"key":"B4","doi-asserted-by":"publisher","first-page":"1516","DOI":"10.1002\/ppul.24442","article-title":"Treatment of pediatric pulmonary arterial hypertension: a focus on the NO-sGC-cGMP pathway","volume":"54","author":"Beghetti","year":"2019","journal-title":"Pediatr Pulmonol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1007\/s40272-019-00374-2","article-title":"Drug treatment of pulmonary hypertension in children","volume":"22","author":"Avitabile","year":"2020","journal-title":"Pediatric Drugs Adis"},{"key":"B6","doi-asserted-by":"publisher","first-page":"2645","DOI":"10.1111\/bcp.14676","article-title":"Riociguat: clinical research and evolving role in therapy","volume":"87","author":"Klinger","year":"2021","journal-title":"Br J Clin Pharmacol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1056\/NEJMoa1209655","article-title":"Riociguat for the treatment of pulmonary arterial hypertension","volume":"369","author":"Ghofrani","year":"2013","journal-title":"N Engl J Med"},{"key":"B8","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1056\/NEJMoa1209657","article-title":"Riociguat for the treatment of chronic thromboembolic pulmonary hypertension","volume":"369","author":"Ghofrani","year":"2013","journal-title":"N Engl J Med"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.02425-2016","article-title":"RESPITE: switching to riociguat in pulmonary arterial hypertension patients with inadequate response to phosphodiesterase-5 inhibitors","volume":"50","author":"Hoeper","year":"2017","journal-title":"Eur Respir J"},{"key":"B10","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1016\/S2213-2600(20)30532-4","article-title":"Switching to riociguat versus maintenance therapy with phosphodiesterase-5 inhibitors in patients with pulmonary arterial hypertension (REPLACE): a multicentre, open-label, randomised controlled trial","volume":"9","author":"Hoeper","year":"2021","journal-title":"Lancet Respir Med"},{"key":"B11","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1007\/s00408-018-0100-3","article-title":"Real-World switching to riociguat: management and practicalities in patients with PAH and CTEPH","volume":"196","author":"Gall","year":"2018","journal-title":"Lung"},{"key":"B12","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1183\/09031936.00090614","article-title":"Riociguat for the treatment of pulmonary arterial hypertension: a long-term extension study (patent-2)","volume":"45","author":"Rubin","year":"2015","journal-title":"Eur Respir J"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1177\/2045894020942121","article-title":"Efficacy and safety of riociguat in combination therapy for patients with pulmonary arterial hypertension (PATENT studies)","volume":"10","author":"Ghofrani","year":"2020","journal-title":"Pulm Circ"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1177\/2045893217743123","article-title":"First-in-child use of the oral soluble guanylate cyclase stimulator riociguat in pulmonary arterial hypertension","volume":"8","author":"Spreemann","year":"2018","journal-title":"Pulm Circ"},{"key":"B15","doi-asserted-by":"publisher","first-page":"1314","DOI":"10.1183\/09031936.00105914","article-title":"PATENT PLUS: a blinded, randomised and extension study of riociguat plus sildenafil in pulmonary arterial hypertension","volume":"45","author":"Gali\u00e8","year":"2015","journal-title":"Eur Respir J"},{"key":"B16","doi-asserted-by":"publisher","first-page":"S75","DOI":"10.1086\/685647","article-title":"Population pharmacokinetics of single-dose riociguat in patients with renal or hepatic impairment","volume":"6","author":"Saleh","year":"2016","journal-title":"Pulm Circ"},{"key":"B17","doi-asserted-by":"publisher","first-page":"S5","DOI":"10.1086\/685015","article-title":"Assessment of the effects of hepatic impairment and smoking on the pharmacokinetics of a single oral dose of the soluble guanylate cyclase stimulator riociguat (BAY 63-2521)","volume":"6","author":"Frey","year":"2016","journal-title":"Pulm Circ"},{"key":"B18","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1097\/00000542-199907000-00041","article-title":"Sildenafil ameliorates effects of inhaled nitric oxide withdrawal","volume":"91","author":"Andrew","year":"1999","journal-title":"Anesthesiology"},{"key":"B19","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1152\/ajpheart.2001.281.1.H124","article-title":"Endothelin-1 and nitric oxide synthase in short rebound reaction to short exposure to inhaled nitric oxide","volume":"281","author":"Chen","year":"2001","journal-title":"Am J Physiol Hear Circ Physiol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1097\/00003246-200201000-00014","article-title":"Cause of rebound pulmonary hypertension","volume":"30","author":"Pearl","year":"2002","journal-title":"Crit Care Med"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1152\/ajpheart.2001.280.2.h777","article-title":"Inhaled nitric oxide-induced rebound pulmonary hypertension: role for endothelin-1","author":"Mcmullan","year":"2001","journal-title":"Am J Physiol Hear Circ Physiol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD011205.pub2","article-title":"Guanylate cyclase stimulators for pulmonary hypertension","author":"Wardle","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1161\/CIR.0000000000000329","article-title":"Pediatric pulmonary hypertension","author":"Abman","year":"2015","journal-title":"Circulation"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01916-2018","article-title":"Paediatric pulmonary arterial hypertension: updates on definition, classification, diagnostics and management","volume":"53","author":"Rosenzweig","year":"2019","journal-title":"Eur Respir J"},{"key":"B25","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.2147\/DDDT.S117277","article-title":"Riociguat: a soluble guanylate cyclase stimulator for the treatment of pulmonary hypertension","volume":"11","author":"Lian","year":"2017","journal-title":"Drug Des Devel Ther"},{"key":"B26","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1183\/09031936.00114407","article-title":"Expression and function of soluble guanylate cyclase in pulmonary arterial hypertension","volume":"32","author":"Schermuly","year":"2008","journal-title":"Eur Respir J"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1111\/j.1527-3466.2007.00003.x","article-title":"Nitric oxide-independent stimulation of soluble guanylate cyclase with BAY 41-2272 in cardiovascular disease","author":"Boerrigter","year":"2007","journal-title":"Authors J Comp C"},{"key":"B28","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1056\/NEJM199507273330403","article-title":"Reduced expression of endothelial nitric oxide synthase in the lungs of patients with pulmonary hypertension","volume":"333","author":"Giaid","year":"1995","journal-title":"N Engl J Med"},{"key":"B29","doi-asserted-by":"publisher","first-page":"1746","DOI":"10.1096\/fj.04-2317fje","article-title":"Increased arginase II and decreased NO synthesis in endothelial cells of patients with pulmonary arterial hypertension","volume":"18","author":"Xu","year":"2004","journal-title":"FASEB J"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1164\/ajrccm.158.3.9802066","article-title":"Biochemical reaction products of nitric oxide as quantitative markers of primary pulmonary hypertension","author":"Kaneko","year":"1998","journal-title":"Am J Respir Crit Care Med"},{"key":"B31","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1136\/thx.52.12.1051","article-title":"Decreased nitric oxide in the exhaled air of patients with systemic sclerosis with pulmonary hypertension","volume":"52","author":"Kharitonov","year":"1997","journal-title":"Thorax"},{"key":"B32","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1016\/j.chest.2016.05.024","article-title":"Riociguat: mode of action and clinical development in pulmonary hypertension","volume":"151","author":"Ghofrani","year":"2017","journal-title":"Chest"},{"key":"B33","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1161\/CIRCRESAHA.107.161463","article-title":"Hyperoxia increases phosphodiesterase 5 expression and activity in ovine fetal pulmonary artery smooth muscle cells","volume":"102","author":"Farrow","year":"2008","journal-title":"Circ Res"},{"key":"B34","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1016\/j.pharmthera.2009.02.009","article-title":"Cyclic GMP signaling in cardiovascular pathophysiology and therapeutics","volume":"122","author":"Tsai","year":"2009","journal-title":"Pharmacol Ther"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0191239","article-title":"Riociguat versus sildenafil on hypoxic pulmonary vasoconstriction and ventilation\/ perfusion matching","volume":"13","author":"Chamorro","year":"2018","journal-title":"PLoS One"},{"key":"B36","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1089\/ars.2011.4184","article-title":"Brief hyperoxia increases mitochondrial oxidation and increases phosphodiesterase 5 activity in fetal pulmonary artery smooth muscle cells","volume":"17","author":"Farrow","year":"2012","journal-title":"Antioxidants Redox Signal"},{"key":"B37","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1016\/j.resp.2010.08.018","article-title":"Mitochondrial oxidant stress increases PDE5 activity in persistent pulmonary hypertension of the newborn","volume":"174","author":"Farrow","year":"2010","journal-title":"Respir Physiol Neurobiol"},{"key":"B38","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1164\/rccm.200712-1839OC","article-title":"Neonatal hyperoxia enhances the inflammatory response in adult mice infected with influenza A virus","volume":"177","author":"O\u2019Reilly","year":"2008","journal-title":"Am J Respir Crit Care Med"},{"key":"B39","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1165\/rcmb.2013-0118OC","article-title":"Disrupted pulmonary artery cyclic guanosine monophosphate signaling in mice with hyperoxia-induced pulmonary hypertension","volume":"50","author":"Lee","year":"2014","journal-title":"Am J Respir Cell Mol Biol"},{"key":"B40","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1053\/j.semperi.2015.12.004","article-title":"Pharmacologic strategies in neonatal pulmonary hypertension other than nitric oxide","volume":"40","author":"Lakshminrusimha","year":"2016","journal-title":"Semin Perinatol"},{"key":"B41","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1152\/ajplung.00138.2010","article-title":"Cinaciguat, a soluble guanylate cyclase activator, augments cGMP after oxidative stress and causes pulmonary vasodilation in neonatal pulmonary hypertension","volume":"301","author":"Chester","year":"2011","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"key":"B42","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1152\/ajplung.00062.2009","article-title":"Cinaciguat, a soluble guanylate cyclase activator, causes potent and sustained pulmonary vasodilation in the ovine fetus","volume":"297","author":"Chester","year":"2009","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"key":"B43","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1152\/ajplung.00409.2004","article-title":"Effects of BAY 41-2272, a soluble guanylate cyclase activator, on pulmonary vascular reactivity in the ovine fetus","volume":"288","author":"Deruelle","year":"2005","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"key":"B44","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1016\/j.rmed.2016.08.022","article-title":"Anti-fibrotic effects of soluble guanylate cyclase stimulators and activators: a review of the preclinical evidence","volume":"122","author":"Sandner","year":"2017","journal-title":"Respir Med"},{"key":"B45","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1161\/CIRCULATIONAHA.105.581405","article-title":"Activation of soluble guanylate cyclase reverses experimental pulmonary hypertension and vascular remodeling","volume":"113","author":"Dumitrascu","year":"2006","journal-title":"Circulation"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0199927","article-title":"Riociguat prevents hyperoxia-induced lung injury and pulmonary hypertension in neonatal rats without effects on long bone growth","volume":"13","author":"Donda","year":"2018","journal-title":"PLoS One"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2210-11-S1-O9","article-title":"Nitric oxide-independent stimulation of soluble guanylate cyclase attenuates pulmonary fibrosis","volume":"11","author":"Evgenov","year":"2011","journal-title":"BMC Pharmacol"},{"key":"B48","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/journal.pone.0043433","article-title":"The soluble guanylate cyclase stimulator riociguat ameliorates pulmonary hypertension induced by hypoxia and SU5416 in rats","volume":"7","author":"Lang","year":"2012","journal-title":"PLoS One"},{"key":"B49","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.1164\/rccm.201311-2037OC","article-title":"Stimulation of soluble guanylate cyclase prevents cigarette smoke-induced pulmonary hypertension and emphysema","volume":"189","author":"Weissmann","year":"2014","journal-title":"Am J Respir Crit Care Med"},{"key":"B50","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1161\/CIRCRESAHA.113.301141","article-title":"Inflammation and immunity in the pathogenesis of pulmonary arterial hypertension","volume":"115","author":"Rabinovitch","year":"2014","journal-title":"Circ Res"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01887-2018","article-title":"Pathology and pathobiology of pulmonary hypertension: state of the art and research perspectives","volume":"53","author":"Humbert","year":"2019","journal-title":"Eur Respir J"},{"key":"B52","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1111\/j.1365-2125.2005.02383.x","article-title":"Bosentan decreases the plasma concentration of sildenafil when coprescribed in pulmonary hypertension","volume":"60","author":"Paul","year":"2005","journal-title":"Br J Clin Pharmacol"},{"key":"B53","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1183\/09031936.00213911","article-title":"Riociguat for interstitial lung disease and pulmonary hypertension: a pilot trial","volume":"41","author":"Hoeper","year":"2013","journal-title":"Eur Respir J"},{"key":"B54","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1177\/0192623314546559","article-title":"Oral administration of soluble guanylate cyclase agonists to rats results in osteoclastic bone resorption and remodeling with new bone formation in the appendicular and axial skeleton","volume":"43","author":"Homer","year":"2015","journal-title":"Toxicol Pathol"},{"key":"B55","author":"Garcia","year":"2021"},{"key":"B56","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fmed.2018.00157","article-title":"Using omics to understand and treat pulmonary vascular disease","volume":"5","author":"Hemnes","year":"2018","journal-title":"Front Med"},{"key":"B57","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1111\/bph.15056","article-title":"The application of \u2018omics\u2019 to pulmonary arterial hypertension","volume":"178","author":"Harbaum","year":"2021","journal-title":"Br J Pharmacol"}],"container-title":["Frontiers in Pediatrics"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2022.1014922\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T12:30:20Z","timestamp":1669897820000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2022.1014922\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,1]]},"references-count":57,"alternative-id":["10.3389\/fped.2022.1014922"],"URL":"https:\/\/doi.org\/10.3389\/fped.2022.1014922","relation":{},"ISSN":["2296-2360"],"issn-type":[{"value":"2296-2360","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,1]]},"article-number":"1014922"}}